Linezolid is an alternative to vancomycin for the long-term treatment of gram-positive bacterial orthopedic infections because of its antibacterial spectrum and oral bioavailability, but duration-related myelosuppression could offset its advantages. To evaluate the hematologic effects of these agents, we prospectively studied 65 consecutive adults with gram-positive bacterial orthopedic infections requiring у2 weeks of vancomycin therapy ( ) or linezolid therapy ( ). Trends suggesting higher incidence of hematologic effects n p 52 n p 20 among the patients receiving vancomycin were not significant, regardless of whether the end point was lowest cell count during therapy or change from baseline. The only difference was a higher incidence of thrombocytopenia (! platelets/L) in the subset of the linezolid recipients who had received vancomycin within ). All hematologic effects were reversible. In conclusion, P p .02 hematologic effects were detectable through weekly monitoring and were reversible; therefore, concern about myelosuppression need not preclude linezolid use for orthopedic infections requiring long-term therapy.
Linezolid, the first oxazolidinone, is an attractive alternative to vancomycin for treatment of postoperative bone and joint infections because of its antibacterial spectrum and pharmacokinetic profile. Linezolid has activity against gram-positive bacteria including methicillin-resistant S. aureus (MRSA) and vancomycinresistant enterococci (VRE). In controlled clinical trials, linezolid was as effective as vancomycin in eradicating infections caused by these pathogens [1, 2] . In addition, the oral formulation of linezolid is 100% bioavailable, thereby providing an opportunity for cost savings by switching patients to oral therapy and reducing the length of hospitalization [3] [4] [5] . Oral therapy is particularly relevant for orthopedic infections because of the need for long-term treatment. Linezolid also provides an alternative for patients who experience vancomycinrelated adverse effects or vancomycin treatment failure. However, reversible myelosuppression, reported in patients receiving linezolid for 12 weeks [6] [7] [8] [9] [10] [11] [12] [13] , could offset these advantages.
The Musculoskeletal Infection Center in our institution (University of Pittsburgh Medical Center), which has dedicated orthopedic surgeons and a musculoskeletal infectious disease specialist, serves as a large referral base for adults with bone and joint infections, most of which are due to drug-resistant staphylococci and require 6-8 weeks of antistaphylococcal therapy. Given the number of patients receiving vancomycin or linezolid therapy, we had a unique opportunity to study the hematologic effects of these drugs. To evaluate the relative hematologic effects of long-term treatment with these two antistaphylococcal antibiotics, we performed a prospective observational study of consecutive adults with orthopedic infections.
METHODS
Patients. This was a prospective, nonrandomized, observational study. Adult patients with chronic osteomyelitis or prosthetic joint infections caused by gram-positive bacterial infections were enrolled consecutively between November 1999 and December 2001. Patients were excluded if they did not complete at least 2 weeks of vancomycin or linezolid therapy. Patients were also excluded if they had thrombocytopenia, neutropenia, or anemia, except for 3 patients who were switched from vancomycin therapy to linezolid therapy because of neutropenia. Written informed consent and institutional review board approval were not obtained because patients were treated according to local standards of care; no clinical interventions were made based on data collected.
Interventions. Vancomycin therapy was the preferred therapy for patients with methicillin-resistant gram-positive bacterial infection. The vancomycin dosage was 15 mg/kg/day adjusted according to creatinine clearance to maintain peak levels of 30-40 mg/mL and trough levels of 10-15 mg/mL. Linezolid was administered if patients were allergic to vancomycin, experienced adverse effects, experienced vancomycin treatment failure, or required oral therapy. The linezolid dosage was 600 mg every 12 h; administration was intravenous at first and, as soon as possible after surgery was switched to oral administration. Complete blood counts were determined at baseline and monitored weekly throughout the study period. Treatment was stopped if the platelet count was ! platelets/L, 9 100 ϫ 10 the absolute neutrophil count was ! neutrophils/L, or 9 1.5 ϫ 10 the hemoglobin level was !90 g/L.
No other drugs were administered that may have been associated with adverse hematologic effects. For example, heparin flushes were prohibited.
Definitions. Osteomyelitis was defined as clinical, radiological, and histopathologic evidence of inflammation of the bone; isolation of a pathogen from culture of bone or tissue samples obtained during surgical debridement or aspiration of the infected bone was required for each patient. Prosthetic joint infection was defined as clinical and ancillary diagnostic evidence of an infected prosthesis; у2 intraoperative tissue cultures for the same organism were required for each patient. Thrombocytopenia was defined as a platelet count of !150 ϫ 10 9 platelets/L. Neutropenia was defined as an absolute neutrophil count of ! neutrophils/L. Anemia was defined 9 1.5 ϫ 10 as a hemoglobin level of !90 g/L. Vancomycin treatment failure was defined as persistent positive cultures for the original organism and sustained clinical and radiological evidence of active osteomyelitis.
Assessments and statistics. The methods for assessing hematologic parameters were based on those used elsewhere [14] , and included lowest cell counts during therapy and percentage change in cell counts from baseline. Incidences of thrombocytopenia, more-severe thrombocytopenia ( 
RESULTS

Patients.
A total of 65 patients were treated either with vancomycin ( ) or linezolid ( ), including 7 patients n p 52 n p 20 who had received vancomycin within 2 weeks before starting linezolid therapy (hereafter, "the linezolid subset who had received vancomycin"). Baseline platelet counts were higher among patients receiving vancomycin therapy (hereafter,"the vancomycin group") than among patients receiving linezolid therapy (hereafter, "the linezolid group") (mean values ‫ע‬ SDs, 359 ϫ 10 9 ‫ע‬ 116 ϫ 10 9 platelets/L vs. 291 ϫ 10 9 ‫ע‬ 86 ϫ 10 9 platelets/L; ). The trend toward lower baseline counts P p .02 among patients in the linezolid subset who had received vancomycin than in the linezolid recipients who had not received vancomycin was not significant (mean values ‫ע‬ SDs, 254 ϫ 10 9 ‫ע‬ 97 ϫ 10 9 platelets/L vs. 311 ϫ 10 9 ‫ע‬ 76 ϫ 10 9 platelets/L; ). There were no differences in baseline neutrophil P p .17 counts between treatment groups.
In the vancomycin group, the median duration of therapy was 42 days; the mean was 41.7 days (range, 10-149 days). 20 . Indications for linezolid therapy were as follows: history of vancomycin allergy (7 patients), vancomycin therapy failure (4), need for oral therapy (4), vancomycin-induced neutropenia (3), need for suppressive therapy after completing vancomycin therapy in a patient with chronic MRSA infection (1), and trimethoprim-sulfamethoxazole therapy failure (1).
Hematologic effects. There were no significant differences in platelet counts between treatment groups, regardless of whether they were measured by lowest count during therapy or by change from baseline (table 2). Thrombocytopenia occurred in 11 patients in the vancomycin group and in 7 in the linezolid group. In the linezolid group, thrombocytopenia occurred in more patients who had received vancomycin within 2 weeks before starting linezolid therapy than in patients who had not (5 ). P p .02 When mean duration of therapy was considered, the rates of thrombocytopenia were 5.1 cases/1000 days of therapy in the vancomycin group and 3.3 cases/1000 days of therapy in the linezolid group. Platelet counts decreased to ! plate-9 100 ϫ 10 lets/L in 1 and 3 patients, respectively, corresponding to rates of 0.9 and 1.4 cases/1000 days of therapy, respectively. The mean decrease in the platelet count from baseline was 39% in the vancomycin group, 38% in the linezolid group, 45% in the linezolid subset who had received vancomycin, and 34% in the linezolid recipients who had not received vancomycin (P 1 ) (figure 1). In both groups, thrombocytopenia had a gradual .05 onset and was reversible after discontinuing therapy (figure 2).
Neutropenia occurred in 6 patients in the vancomycin group and in 1 in the linezolid group (table 2). When duration of therapy was considered, there was a trend toward a higher rate of neutropenia in the vancomycin group than in the linezolid group (2.8 vs. 0.5 cases/1000 days of therapy;
). The P p .07 mean decrease in the neutrophil count from baseline was 41% in the vancomycin group and 28% in the linezolid group ( ). The mean nadir count was neutrophils/L 9 P p .09 2.4 ϫ 10 (range, to neutrophils/L) in the vancomy- 9 9 0.5 ϫ 10 4.9 ϫ 10 cin group and neutrophils/L (range, 0.9 ϫ 10 9 to 9 2.8 ϫ 10 neutrophils/L) in the linezolid group. In both groups, 9 5.3 ϫ 10 neutropenia had a gradual onset and was reversible after discontinuing therapy. In the 1 patient in the linezolid group, neutropenia occurred 31 days after beginning linezolid therapy, resolved spontaneously during therapy, reappeared ∼65 days later, and was reversed almost immediately after stopping linezolid therapy.
Anemia occurred in 0 patients in the vancomycin group and in 2 in the linezolid group. This corresponded to a rate of 0 and 1 case/1000 days of therapy, respectively ( ). P 1 .05 Treatment was stopped because of hematologic effects in 5 patients in the vancomycin group and in 3 in the linezolid group. Vancomycin therapy was stopped because the platelet count decreased to ! platelets/L in 1 patient and be-9 100 ϫ 10 cause of neutropenia in 4 patients. Two other patients had neutropenia but were allowed to continue vancomycin therapy because they were within 2 weeks of completing therapy; they were monitored carefully and did not receive supportive care with other medications, such as filgrastim. Linezolid therapy was stopped because the platelet count decreased to !100 ϫ 10 9 platelets/L in 2 patients, including 1 who also had anemia, and because of neutropenia in 1 patient. One other patient had a platelet count that decreased to ! platelets/L but 9 100 ϫ 10 was allowed to continue linezolid therapy because she was within 2 weeks of completing therapy.
Clinical effects.
None of the patients in either treatment group experienced adverse clinical effects attributable to thrombocytopenia, neutropenia, or anemia.
DISCUSSION
In this prospective, observational study, we did not find any evidence of an increased risk of myelosuppression during longterm linezolid therapy, compared with long-term vancomycin therapy, even after assessing hematologic parameters in different ways. In fact, adverse hematologic effects appeared to be more common in the vancomycin group, but these trends were not significant. The only significant difference was a higher incidence of thrombocytopenia in the linezolid subset who had received vancomycin than in the linezolid recipients who had not received vancomycin, suggesting that recent treatment with vancomycin increased the risk for patients whose therapy was switched to linezolid. Waldrep and colleagues [9] also described a case of MRSA sternal osteomyelitis in which vancomycin was administered before the onset of thrombocytopenia during linezolid therapy. Treatment with vancomycin might have been a contributing factor in other reports of linezolid-related myelosuppression in which exposure to vancomycin was not specified [6, 7, [10] [11] [12] [13] . On the other hand, Chien and colleagues [8] described 2 patients whose therapy was switched from vancomycin because of myelosuppression, which resolved during linezolid therapy. To the best of our knowledge, this is the first prospective comparison of the hematologic effects of long-term therapy with linezolid and those of long-term therapy with vancomycin (median, 71 vs. 42 days). Analysis of long-term therapy is relevant because the risk of myelosuppression is thought to increase with increasing duration of therapy [6, 7, [9] [10] [11] [13] [14] [15] . Many of our patients had deep-seated orthopedic infections involving prosthetic implants or posttraumatic osteomyelitis with the presence of implanted devices and requiring additional reconstructive therapy. Our patients had some underlying diseases, such as diabetes or rheumatologic diseases, but they did not have HIV infection, were not transplant recipients, and did not receive disease-modifying biologic agents for rheumatoid arthritis. Therefore, the primary distinguishing feature of our patient population was the need for prolonged, sequential therapy.
In our study, hematologic effects were detected through weekly monitoring of blood counts. Thrombocytopenia had a gradual onset, occurring a mean of 40 days after the start of linezolid therapy, and was reversible 7-10 days after linezolid therapy was stopped. Neutropenia, detected in only 1 patient, occurred ∼30 days after beginning linezolid therapy, resolved spontaneously, reappeared ∼65 days later, and was reversed almost immediately after stopping linezolid therapy. There was no evidence of bleeding or any other clinical complications attributable to thrombocytopenia, neutropenia, or anemia in either treatment group.
We are aware of 2 retrospective analyses of the hematologic effects of linezolid therapy in patients enrolled in large, controlled trials [14] [15] [16] . As in our study, there were no significant differences in hematologic effects between treatment groups; however, in contrast to our study, most patients received linezolid for 10-14 days, except for patients with VRE infection, who were treated for 28 days. In 12000 patients who had complicated skin and soft-tissue infection, pneumonia, or VRE infection, and who received either linezolid or comparator drugs (which included ceftriaxone, cefpodoxime, oxacillin, and vancomycin), the incidences of thrombocytopenia (2.4% vs. 1.5% of patients, ), and anemia (0.7% vs. 0.2% of patients) P 1 .05 were similar [14, 15] . In ∼350 patients who received at least 5 days of treatment with linezolid and had nosocomial pneumonia, the incidences of thrombocytopenia were similar among linezolid recipients and among vancomycin recipients (2.8% of recipients vs. 3.6%;
) [16] . P 1 .05 Different definitions of thrombocytopenia have been used. For example, the manufacturer of linezolid defines a substantially low platelet count as !75% of the lower limit of the normal and/or the baseline count [17] . Our definition of thrombocytopenia-a platelet count of !150 ϫ 10 9 platelets/ L-is consistent with that used in at least 1 of the retrospective reviews [14] . To detect more-severe thrombocytopenia, we evaluated platelet counts that decreased to ! platelets/L, 9 100 ϫ 10 which was the criterion for stopping therapy. To capture data from patients who had low baseline values, we evaluated the lowest count during therapy and the percentage change from baseline.
Reversible hematologic effects have been reported in patients receiving vancomycin. Thrombocytopenia, which is character- 145 ϫ 10 platelets/L from day 100 until linezolid therapy was stopped; the platelet count was platelets/L on day 314. 9 9 149 ϫ 10 234 ϫ 10
ized by increased numbers of megakaryocytes in the bone marrow, may be caused by a direct toxic effect or hapten formation, or may be an "innocent bystander" effect [18] [19] [20] . Neutropenia is usually detectable у1 week after the start of therapy or after receipt of a total dosage of 125 g [21, 22] . In a retrospective review of 98 patients who received 100 courses of vancomycin, neutropenia was noted in 2% of patients and was rapidly reversible [23] . The incidence of neutropenia was higher in our series. The mechanism of neutropenia is unknown; however, new evidence suggests an immunologic basis [22, 24] . Although we did not evaluate the mechanism per se, only 1 of the 11 patients who developed thrombocytopenia received vancomycin within the previous month, whereas 2 of the 6 patients who developed neutropenia received it within the previous 2 weeks. Furthermore, many had deep-seated orthopedic infections that had required multiple courses of antibiotics, but none of the patients had received linezolid previously. These findings suggest the possibility of immune-mediated effects. Filgrastim has been used to mitigate vancomycin-induced neutropenia in patients requiring long-term vancomycin therapy for the treatment of orthopedic infections [25] , but we did not administer this or any other supportive interventions.
Our study had some limitations. First, it was not a randomized comparison of treatment groups stratified by risk factors for hematologic effects. Any bias, however, likely favored vancomycin, because it was the preferred antibiotic and had a shorter duration of exposure. Furthermore, there has never been a prospectively randomized, comparative study of this issue. Previously published articles are anecdotal case reports [6, 7, 9, 11, 13, 25] , retrospective chart reviews [10, 12] , a description of a compassionate-use program [8] , and retrospective analyses of controlled clinical trials [14] [15] [16] . Second, our study had only 20 patients in the linezolid group and was not powered to detect differences between groups. A significantly higher incidence of hematologic effects in the linezolid group was unlikely, because trends suggested a higher incidence of hematologic effects in the vancomycin group.
In conclusion, we detected hematologic effects through weekly monitoring of blood counts in patients receiving longterm linezolid therapy for orthopedic infections, but the incidence was not higher in this group than in the vancomycin group. Hematologic effects had a gradual onset, were related to duration of therapy, and were reversible in all patients. It is interesting to note that the incidence of thrombocytopenia ap-peared to be increased by prior administration of vancomycin. Well-designed studies are needed to confirm the conclusions from our prospective observational study. In the absence of such studies-and given the limited number of antimicrobial agents with activity against MRSA, need for prolonged therapy for orthopedic infection, and desirability of an oral formulation-concern regarding myelosuppression need not preclude the use of linezolid for treatment of most patients. However, it is imperative that these patients be closely monitored for hematologic effects.
